A Study of Lu AF82422 in Participants With Multiple System Atrophy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

November 16, 2023

Study Completion Date

March 7, 2028

Conditions
Multiple System Atrophy
Interventions
DRUG

Lu AF82422

Solution for infusion

DRUG

Placebo

Solution for infusion

Trial Locations (19)

10016

NYU Langone Health Medical Center, New York

10032

Columbia University Medical Center - The Neurological Institute of New York, New York

15213

University Of Pittsburgh, Pittsburgh

17033

Penn State Milton S. Hershey Medical Center - Penn State Hershey Neuroscience Institute (PSHNI), Hershey

19107

University of Pennsylvania, Philadelphia

32608

University of Florida Norman Fixel Institute for Neurological Diseases, Gainesville

33486

Parkinson's Disease And Movement Disorder Center Of Boca Raton, Boca Raton

55905

Mayo Clinic, Rochester

60026

Endeavor Health - Glenbrook Hospital, Glenview

60612

Rush University Medical Center, Rush University Cancer Center, Chicago

80113

CenExel Rocky Mountain Clinical Research, LLC, Englewood

92037

University of California - San Diego, La Jolla

92708

The Parkinsons and Movement Disorder Institute, Fountain Valley

94158

University of California, San Francisco Neurosciences Clinical Research Unit, San Francisco

02215

Beth Israel Deaconess Medical Center, Boston

68198-8440

University Nebraska Medical Center, Omaha

470-1192

Fujita Health University Hospital, Toyoake

501-1194

Gifu University Hospital, Gifu

982-8555

National Hospital Organization Sendai Nishitaga Hospital, Sendai

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT05104476 - A Study of Lu AF82422 in Participants With Multiple System Atrophy | Biotech Hunter | Biotech Hunter